CoChat
Sign Up
Cited by 164SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

Current advances in the development of SARS-CoV-2 vaccines

Open access
Awadasseid, Annoor, Wu, Yanling, Tanaka, Yoshimasa, Zhang, Wen·2021·International Journal of Biological Sciences
DOI 10.7150/ijbs.52569PMC PMC7757035
Open this paper in CoChat — free accountOpen PDF

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic that has wreaked havoc globally, which has put a heavy toll on public health, lives, and the world economy. Vaccination is considered as one of the greatest successes in medical history. Based on prior experience with the development of SARS-CoV vaccines, all COVID-19 vaccines must be subjected to the tests for protective effects and harmful risks derived from antibody-dependent enhancement that may contribute to augmented infectivity and/or eosinophilic infiltration. The SARS-CoV-2 vaccine is now being developed urgently in several different ways. China is regarded as one of the world's leading countries in SARS-CoV-2 vaccine development, up to date the last inactivated vaccine international clinical (Phase III) trial was launched in the United Arab Emirates by Sinopharm China National Biotec Group (CNBG). In this review, we outline the current status of vaccine development against clinically relevant SARS-CoV-2 strains, anticipating that such attempts would help create efficacious and sage SARS-CoV-2 vaccines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/ijbs.52569

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Disadvantages of inactivated vaccines include limited immunogenicity requiring adjuvants, large quantities of live virus to be handled, and integrity of antigens or epitopes that should be verified.

    “Disadvantages include limited immunogenicity requiring adjuvants to enhance the immune response, large quantities of live virus to be handled, and the integrity of antigens or epitopes that should be verified.8”

    From Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey (2021) · cites this paper as [8]

    The Safety section (page unavailable) says adjuvants can improve vaccine immunogenicity, and Selection of antigens > Whole-cell antigen says killed-virus vaccines require careful quality assurance. Neither passage says inactivated vaccines have limited immunogenicity requiring adjuvants, require handling large quantities of live virus, or specifically require verification of antigen or epitope integrity. Searches for those terms found no more direct support. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 71

  1. [1]Awadasseid A Wu Y Tanaka Y Zhang W Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China International Journal of Biological Sciences 2020 16 1846 60 http://www.ijbs.com/v16p.htm 32398954 PMC7211182
  2. [3]Zhu N Zhang D Wang W Li X Yang B Song J A novel coronavirus from patients with pneumonia in China, 2019 New England Journal of Medicine 2020 DOI: 10.1056/NEJMoa2001017 PMC7092803 31978945 · DOI · Paper page
  3. [9]WHO. Middle East respiratory syndrome coronavirus (MERS-CoV)—Republic of Korea. 2015 https://www.who.int/csr/don/25-october-2015-mers-korea/en/ PMC4561741 26356871
  4. [10]Padron-Regalado E Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains Infectious diseases and therapy 2020 1 20 https://doi.org/10.1007/s40121-020-00300-x PMC7177048 32328406 · DOI
  5. [12]Guo Y-R Cao Q-D Hong Z-S Tan Y-Y Chen S-D Jin H-J The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status Military Medical Research 2020 7 1 10 32169119 PMC7068984
  6. [13]Phan T Novel coronavirus: From discovery to clinical diagnostics Infection, Genetics and Evolution 2020 79 104211. https://doi.org/10.1016/j.meegid.2020 PMC7129799 32007627 · DOI
  7. [14]Hoffmann M Kleine-Weber H Schroeder S Krüger N Herrler T Erichsen S SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell. 2020; https://doi.org/10.1016/j.cell 2020 02.052 PMC7102627 32142651 · DOI
  8. [15]Remy V Largeron N Quilici S Carroll S The Economic Value of Vaccination: Why Prevention Is Wealth Value in Health 2014 17 A 450. DOI: https://doi.org/10.1016/j.jval.2014.08.1211 27201236 · DOI
  9. [16]Du L He Y Zhou Y Liu S Zheng B-J Jiang S The spike protein of SARS-CoV—a target for vaccine and therapeutic development Nature reviews Microbiology 2009 7 226 36 19198616 PMC2750777
  10. [17]Petrovsky N Aguilar JC Vaccine adjuvants: current state and future trends Immunology and cell biology 2004 82 488 96 15479434
  11. [18]Lauer KB Borrow R Blanchard TJ Multivalent and multipathogen viral vector vaccines Clin Vaccine Immunol 2017 24 e00298 16 27535837 PMC5216423
  12. [19]Urakami A Sakurai A Ishikawa M Yap ML Flores-Garcia Y Haseda Y Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus Clin Vaccine Immunol 2017 24 e00090 17 28515133 PMC5498722
  13. [20]Lin J Zhang J-S Su N Xu J-G Wang N Chen J-T Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine Antiviral therapy 2007 12 1107 18018769
  14. [21]Martin JE Louder MK Holman LA Gordon IJ Enama ME Larkin BD A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial Vaccine 2008 26 6338 43 18824060 PMC2612543
  15. [23]Zhao L Seth A Wibowo N Zhao C-X Mitter N Yu C Nanoparticle vaccines Vaccine 2014 32 327 37 24295808
  16. [24]Modjarrad K Roberts CC Mills KT Castellano AR Paolino K Muthumani K Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial The Lancet Infectious Diseases 2019 19 1013 22 31351922 PMC7185789
  17. [27]Schindewolf C Menachery VD Middle east respiratory syndrome vaccine candidates: cautious optimism Viruses 2019 11 74 PMC6356267 30658390
  18. [28]Xia S Liu Q Wang Q Sun Z Su S Du L Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein Virus research 2014 194 200 10 25451066 PMC7114414
  19. [29]Amanat F Krammer F SARS-CoV-2 vaccines: status report Immunity. 2020; https://doi.org/10.1016/j.immuni 2020 03.007 PMC7136867 32259480 · DOI
  20. [32]Zhou Z Post P Chubet R Holtz K McPherson C Petric M A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice Vaccine 2006 24 3624 31 16497416 PMC7115485
  21. [34]Anderson EJ Rouphael NG Widge AT Jackson LA Roberts PC Makhene M Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults New England Journal of Medicine. 2020:. DOI: 10.1056/NEJMoa2028436 PMC7556339 32991794 · DOI · Paper page
  22. [35]Kumar P Sah AK Tripathi G Kashyap A Tripathi A Rao R Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19 Molecular and Cellular Biochemistry 2020 1 22 https://doi.org/10.1007/s11010-020-03924-2 PMC7539757 33029696 · DOI
  23. [36]Lu S Timely development of vaccines against SARS-CoV-2 Emerging Microbes & Infections 2020 9 542 4 32148172 PMC7144304
  24. [37]Haynes BF Gilbert PB McElrath MJ Zolla-Pazner S Tomaras GD Alam SM Immune-correlates analysis of an HIV-1 vaccine efficacy trial New England Journal of Medicine 2012 366 1275 86 PMC3371689 22475592
  25. [38]Lu S Editorial overview: vaccines against challenging viral pathogens and new vaccine technology DOI: 10.1016/j.coviro.2014.04.006 2014 24831092 · DOI
  26. [40]Rudraraju R Mordant F Subbarao K How live attenuated vaccines can inform the development of broadly cross-protective influenza vaccines The Journal of infectious diseases 2019 219 S81 S7 30715386 PMC7313962
  27. [46]Jiang S Bottazzi ME Du L Lustigman S Tseng C-TK Curti E Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome Expert review of vaccines 2012 11 1405 13 23252385 PMC3586247
  28. [47]Coleman CM Liu YV Mu H Taylor JK Massare M Flyer DC Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice Vaccine 2014 32 3169 74 24736006 PMC4058772
  29. [49]Chen W-H Chag SM Poongavanam MV Biter AB Ewere EA Rezende W Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate Journal of pharmaceutical sciences 2017 106 1961 70 28456726 PMC5612335
  30. [50]Chen W-H Du L Chag SM Ma C Tricoche N Tao X Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate Human vaccines & immunotherapeutics 2014 10 648 58 24355931 PMC4130269
  31. [51]Chen W-H Strych U Hotez PJ Bottazzi ME The SARS-CoV-2 vaccine pipeline: an overview Current tropical medicine reports 2020 1 4 https://doi.org/10.1007/s40475-020-00201-6 PMC7094941 32219057 · DOI
  32. [52]Barteling S Development and performance of inactivated vaccines against foot and mouth disease Revue scientifique et technique-Office international des épizooties 2002 21 577 83 12523698
  33. [53]Minor PD Live attenuated vaccines: historical successes and current challenges Virology 2015 479 379 92 25864107
  34. [54]Marohn ME Barry EM Live attenuated tularemia vaccines: recent developments and future goals Vaccine 2013 31 3485 91 23764535 PMC3766925
  35. [56]Lan J Ge J Yu J Shan S Zhou H Fan S Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Nature 2020 1 6 32225176
  36. [57]Zhou Y Jiang S Du L Prospects for a MERS-CoV spike vaccine Expert review of vaccines 2018 17 677 86 30058403 PMC6355461
  37. [58]Zakhartchouk AN Sharon C Satkunarajah M Auperin T Viswanathan S Mutwiri G Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine Vaccine 2007 25 136 43 16919855 PMC7115608
  38. [59]Woo PC Lau SK Tsoi H-w Chen Z-w Wong BH Zhang L SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus Vaccine 2005 23 4959 68 15993989 PMC7115571
  39. [60]He Y Zhou Y Liu S Kou Z Li W Farzan M Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine Biochemical and biophysical research communications 2004 324 773 81 15474494 PMC7092904
  40. [61]Li F Structure, function, and evolution of coronavirus spike proteins Annual review of virology 2016 3 237 61 PMC5457962 27578435
  41. [62]McBride R Van Zyl M Fielding BC The coronavirus nucleocapsid is a multifunctional protein Viruses 2014 6 2991 3018 25105276 PMC4147684
  42. [63]Leung DTM Chi Hang TF Chun Hung M Sheung Chan PK Cheung JLK Niu H Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid The Journal of infectious diseases 2004 190 379 86 15216476 PMC7110057
  43. [64]Kim TW Lee JH Hung C-F Peng S Roden R Wang M-C Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus Journal of virology 2004 78 4638 45 15078946 PMC387705
  44. [65]Collisson EW Pei J Dzielawa J Seo SH Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry Developmental & Comparative Immunology 2000 24 187 200 10717287
  45. [66]Seo SH Pei J Briles WE Dzielawa J Collisson EW Adoptive transfer of infectious bronchitis virus primed αβ T cells bearing CD8 antigen protects chicks from acute infection Virology 2000 269 183 9 10725210 PMC7131381
  46. [67]Buchholz UJ Bukreyev A Yang L Lamirande EW Murphy BR Subbarao K Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity Proceedings of the National Academy of Sciences 2004 101 9804 9 PMC470755 15210961
  47. [68]Neuman BW Kiss G Kunding AH Bhella D Baksh MF Connelly S A structural analysis of M protein in coronavirus assembly and morphology Journal of structural biology 2011 174 11 22 21130884 PMC4486061
  48. [69]Pang H Liu Y Han X Xu Y Jiang F Wu D Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine Journal of general virology 2004 85 3109 13 15448374
  49. [70]Liu J Sun Y Qi J Chu F Wu H Gao F The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes The Journal of infectious diseases 2010 202 1171 80 20831383 PMC7537489
  50. [71]Nieto-Torres JL DeDiego ML Verdia-Baguena C Jimenez-Guardeno JM Regla-Nava JA Fernandez-Delgado R Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis PLoS pathogens 2014 10 PMC4006877 24788150
  51. [73]Vennema H De Groot R Harbour D Dalderup M Gruffydd-Jones T Horzinek M Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization Journal of virology 1990 64 1407 9 2154621 PMC249267
  52. [74]Tseng C-T Sbrana E Iwata-Yoshikawa N Newman PC Garron T Atmar RL Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus PloS one 2012 7 PMC3335060 22536382
  53. [75]Bolles M Deming D Long K Agnihothram S Whitmore A Ferris M A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Journal of virology 2011 85 12201 15 21937658 PMC3209347
  54. [77]Weingartl H Czub M Czub S Neufeld J Marszal P Gren J Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Journal of virology 2004 78 12672 6 15507655 PMC525089
  55. [78]Agrawal AS Tao X Algaissi A Garron T Narayanan K Peng B-H Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus Human vaccines & immunotherapeutics 2016 12 2351 6 27269431 PMC5027702
  56. [79]Zhao J Li K Wohlford-Lenane C Agnihothram SS Fett C Zhao J Rapid generation of a mouse model for Middle East respiratory syndrome Proceedings of the National Academy of Sciences 2014 111 4970 5 PMC3977243 24599590
  57. [80]Houser KV Broadbent AJ Gretebeck L Vogel L Lamirande EW Sutton T Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody PLoS pathogens 2017 13 e1006565 28817732 PMC5574614
  58. [81]Luo F Liao F-L Wang H Tang H-B Yang Z-Q Hou W Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine Virologica Sinica 2018 33 201 4 29541941 PMC6178114
  59. [82]Stadler K Roberts A Becker S Vogel L Eickmann M Kolesnikova L SARS vaccine protective in mice Emerging infectious diseases 2005 11 1312 16110580 PMC3320494
  60. [83]Bukreyev A Lamirande EW Buchholz UJ Vogel LN Elkins WR St Claire M Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS The Lancet 2004 363 2122 7 PMC7112367 15220033
  61. [84]Bisht H Roberts A Vogel L Bukreyev A Collins PL Murphy BR Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice Proceedings of the National Academy of Sciences 2004 101 6641 6 PMC404098 15096611
  62. [85]Kong W-p Xu L Stadler K Ulmer JB Abrignani S Rappuoli R Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization Journal of virology 2005 79 13915 23 16254327 PMC1280202
  63. [86]Greenough TC Babcock GJ Roberts A Hernandez HJ Thomas Jr WD Coccia JA Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice The Journal of infectious diseases 2005 191 507 14 15655773 PMC7110081
  64. [87]Subbarao K McAuliffe J Vogel L Fahle G Fischer S Tatti K Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice Journal of virology 2004 78 3572 7 15016880 PMC371090
  65. [88]Du L Zhao G He Y Guo Y Zheng B-J Jiang S Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model Vaccine 2007 25 2832 8 17092615 PMC7115660
  66. [89]Du L Zhao G Lin Y Chan C He Y Jiang S Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection Vaccine 2008 26 1644 51 18289745 PMC2600875
  67. [90]Wang L Shi W Joyce MG Modjarrad K Zhang Y Leung K Evaluation of candidate vaccine approaches for MERS-CoV Nature communications 2015 6 1 11 PMC4525294 26218507
  68. [91]Hearnden C Lavelle EC Adjuvant strategies for vaccines: the use of adjuvants within the cancer vaccine setting Cancer Immunotherapy: Elsevier 2013 p. 333-49
  69. [92]Honda-Okubo Y Barnard D Ong CH Peng B-H Tseng C-TK Petrovsky N Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology Journal of virology 2015 89 2995 3007 25520500 PMC4337527
  70. [93]Tang X Wu C Li X Song Y Yao X Wu X On the origin and continuing evolution of SARS-CoV-2 National Science Review 2020 https://doi.org/10.1093/nsr/nwaa036 PMC7107875 34676127 · DOI
  71. [94]Neher RA Dyrdak R Druelle V Hodcroft EB Albert J Potential impact of seasonal forcing on a SARS-CoV-2 pandemic Swiss medical weekly 2020 150 DOI https://doi.org/10.4414/smw.2020.20224 32176808 · DOI

Cited by

Sorted by citations

Authors
Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W.
Affiliations
  • Zhejiang University of Technology (CN)
  • Zhejiang Center for Disease Control and Prevention (CN)
  • Nagasaki University (JP)
Corresponding author
  • Wu, Yanling
  • Zhang, Wen
ORCID
Venue
International Journal of Biological Sciences
Publisher
Ivyspring International Publisher
Published
2021
Volume
17
Issue
1
Pages
8-19
ISSN
1449-2288 (ISSN-L)
DOI
10.7150/ijbs.52569
PMC
PMC7757035
OpenAlex
W3097400276
Cited by
164
References
5
Citations by year
2026: 5 · 2025: 6 · 2024: 19 · 2023: 30 · 2022: 55 · 2021: 49
FWCI
1.61
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • International Journal of Biological Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (No. 21877101, 21877101)
  • Key Research and Development Program of Zhejiang Province
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
SARS-CoV-2, COVID-19 vaccines, vaccine development, inactivated vaccine, Sinopharm, antibody-dependent enhancement, vaccine safety, clinical trials, SARS-CoV-2 variants
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review